These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 18374336

  • 1. Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A sub-analysis from the PIOSTAT study.
    Leonhardt W, Pfützner A, Müller J, Pietzsch J, Forst T, Karagiannis E, Lübben G, Hanefeld M.
    Atherosclerosis; 2008 Nov; 201(1):155-62. PubMed ID: 18374336
    [Abstract] [Full Text] [Related]

  • 2. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
    Ose L, Reyes R, Johnson-Levonas AO, Sapre A, Tribble DL, Musliner T.
    Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
    [Abstract] [Full Text] [Related]

  • 3. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease.
    Kontopoulos AG, Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Mayroudi MC, Boudoulas H.
    Coron Artery Dis; 1996 Nov; 7(11):843-50. PubMed ID: 8993943
    [Abstract] [Full Text] [Related]

  • 4. The role of pioglitazone in modifying the atherogenic lipoprotein profile.
    Hanefeld M.
    Diabetes Obes Metab; 2009 Aug; 11(8):742-56. PubMed ID: 19519869
    [Abstract] [Full Text] [Related]

  • 5. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study.
    Hanefeld M, Marx N, Pfützner A, Baurecht W, Lübben G, Karagiannis E, Stier U, Forst T.
    J Am Coll Cardiol; 2007 Jan 23; 49(3):290-7. PubMed ID: 17239709
    [Abstract] [Full Text] [Related]

  • 6. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ, Watson KE, Talbert RL.
    J Manag Care Pharm; 2008 Oct 23; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [Abstract] [Full Text] [Related]

  • 7. Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins.
    Geiss HC, Otto C, Parhofer KG.
    Metabolism; 2006 May 23; 55(5):599-604. PubMed ID: 16631435
    [Abstract] [Full Text] [Related]

  • 8. Heterogeneous properties of intermediate- and low-density lipoprotein subpopulations.
    Srisawasdi P, Vanavanan S, Rochanawutanon M, Pornsuriyasak P, Tantrakul V, Kruthkul K, Kotani K.
    Clin Biochem; 2013 Oct 23; 46(15):1509-15. PubMed ID: 23830843
    [Abstract] [Full Text] [Related]

  • 9. Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial.
    Lewin AJ, Kipnes MS, Meneghini LF, Plotkin DJ, Perevozskaya IT, Shah S, Maccubbin DL, Mitchel YB, Tobert JA, Simvastatin/Thiazolidinedione Study Group.
    Clin Ther; 2004 Mar 23; 26(3):379-89. PubMed ID: 15110130
    [Abstract] [Full Text] [Related]

  • 10. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
    McCormack T, Harvey P, Gaunt R, Allgar V, Chipperfield R, Robinson P, IN-PRACTICE study.
    Int J Clin Pract; 2010 Jul 23; 64(8):1052-61. PubMed ID: 20487050
    [Abstract] [Full Text] [Related]

  • 11. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study.
    Winkler K, Konrad T, Füllert S, Friedrich I, Destani R, Baumstark MW, Krebs K, Wieland H, März W.
    Diabetes Care; 2003 Sep 23; 26(9):2588-94. PubMed ID: 12941723
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The effect of simvastatin treatment on the low-density lipoprotein subfraction profile and composition in familial hypercholesterolaemia.
    de Graaf J, Demacker PN, Stalenhoef AF.
    Neth J Med; 1993 Dec 23; 43(5-6):254-61. PubMed ID: 8107933
    [Abstract] [Full Text] [Related]

  • 18. Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease.
    Le NA, Tomassini JE, Tershakovec AM, Neff DR, Wilson PW.
    J Am Heart Assoc; 2015 Oct 20; 4(10):e001675. PubMed ID: 26486166
    [Abstract] [Full Text] [Related]

  • 19. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.
    Mora S, Caulfield MP, Wohlgemuth J, Chen Z, Superko HR, Rowland CM, Glynn RJ, Ridker PM, Krauss RM.
    Circulation; 2015 Dec 08; 132(23):2220-9. PubMed ID: 26408274
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.